- Home
- CNF vs KPTI Comparison
CNF vs KPTI Comparison
Compare CNF & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | KPTI |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 36.7M |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CNF | KPTI |
|---|---|---|
| Price | $2.03 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 6.9K | ★ 1.2M |
| Earning Date | 08-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.37 | $0.31 |
| 52 Week High | $6.49 | $10.99 |
Technical Indicators
Market Signals| Indicator | CNF | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 15.51 |
| Support Level | $1.74 | N/A |
| Resistance Level | $2.19 | $2.16 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.63 | 2.62 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).